Narenraj Arulprakash

Researcher

Last publication 2024 Last refreshed 2026-05-02

faculty

5 h-index 12 pubs 83 cited

Biography and Research Information

OverviewAI-generated summary

Narenraj Arulprakash's research focuses on the pharmacological effects of antiplatelet medications, particularly ticagrelor and clopidogrel, in patients with chronic kidney disease. His work has investigated the differential impact of these drugs on platelet aggregation and inflammatory markers in individuals with advanced renal insufficiency. Arulprakash also studies neurological complications and outcomes associated with various medical conditions, including COVID-19 and Wernicke's encephalopathy. His publications have examined the underutilization of stroke care and neurocritical care during the COVID-19 pandemic, as well as atypical presentations of neurological disorders. He has also documented cases of immune-related adverse events, such as myasthenia gravis induced by immune checkpoint inhibitors. Arulprakash has a publication record of 12 works, with an h-index of 5 and 82 total citations.

Metrics

  • h-index: 5
  • Publications: 12
  • Citations: 83

Selected Publications

  • Case of Immune Checkpoint Inhibitor Induced Myasthenia Gravis (2024)
  • Atypical Clinical Presentations and Neuroimaging Findings of Wernicke Encephalopathy (P4-4.004) (2023)
  • Ticagrelor inhibits platelet aggregation and reduces inflammatory burden more than clopidogrel in patients with stages 4 or 5 chronic kidney disease (2023)
    11 citations DOI OpenAlex
  • Cerebellar restricted diffusion in Wernicke’s encephalopathy (2022)
    1 citation DOI OpenAlex
  • Continued Underutilization of stroke care during the COVID-19 pandemic (2021)
    5 citations DOI OpenAlex

View all publications on OpenAlex →

Collaboration Network

32 Collaborators 10 Institutions 2 Countries

Top Collaborators

View profile →
View profile →
View profile →

Similar Researchers

Based on overlapping research topics